These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33247879)

  • 41. Increased Incretin But Not Insulin Response after Oral versus Intravenous Branched Chain Amino Acids.
    Gojda J; Straková R; Plíhalová A; Tůma P; Potočková J; Polák J; Anděl M
    Ann Nutr Metab; 2017; 70(4):293-302. PubMed ID: 28595189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses.
    Engelbrechtsen L; Mahendran Y; Jonsson A; Gjesing AP; Weeke PE; Jørgensen ME; Færch K; Witte DR; Holst JJ; Jørgensen T; Grarup N; Pedersen O; Vestergaard H; Torekov S; Kanters JK; Hansen T
    BMC Genet; 2018 Mar; 19(1):15. PubMed ID: 29548277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes.
    Park SH; Jung MH; Cho WK; Park MS; Suh BK
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):72-9. PubMed ID: 25903996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incretin levels in polycystic ovary syndrome.
    Vrbikova J; Hill M; Bendlova B; Grimmichova T; Dvorakova K; Vondra K; Pacini G
    Eur J Endocrinol; 2008 Aug; 159(2):121-7. PubMed ID: 18511472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
    Deng Y; Zhang Y; Zheng S; Hong J; Wang C; Liu T; Sun Z; Gu W; Gu Y; Shi J; Yao S; Wang W; Ning G
    J Diabetes; 2015 Nov; 7(6):820-9. PubMed ID: 25395350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT.
    Alssema M; Rijkelijkhuizen JM; Holst JJ; Teerlink T; Scheffer PG; Eekhoff EM; Gastaldelli A; Mari A; Hart LM; Nijpels G; Dekker JM
    Eur J Endocrinol; 2013 Oct; 169(4):421-30. PubMed ID: 23864340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus.
    Yoo S; Yang EJ; Koh G
    Diabetes Metab J; 2019 Aug; 43(4):495-503. PubMed ID: 30877705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
    Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
    Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study.
    Mosavat M; Omar SZ; Jamalpour S; Tan PC
    J Diabetes Res; 2020; 2020():9072492. PubMed ID: 32090124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
    Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.